Last Update 21 Mar 26

Fair value Increased 25%

VTRS: Cost Savings And Capital Returns Will Support Future Upside Potential

Analysts have raised the fair value estimate for Viatris to $20 from $16, citing completed cost savings, guidance that is above prior consensus, and expectations for mid single digit revenue growth with higher profit margins, which support a lower future P/E assumption.

Analyst Commentary

Bullish analysts have been leaning more constructive on Viatris, with several price target increases and upgrades pointing to growing confidence in the company’s execution on cost savings and its guidance.

Recent Street research highlights that Viatris has hit key internal milestones and provided guidance that sits above prior consensus expectations, which some analysts view as supportive of a higher fair value range for the stock.

One major firm, UBS, lifted its price target on Viatris to $20 from $18 after the company met its Q4 cost saving goals and issued FY26 guidance above consensus, even though the share price moved 5% lower following earlier year-to-date gains.

Other bullish analysts have also raised targets across the mid teens to $20 range and issued upgrades, pointing to improving confidence in Viatris’ ability to sustain higher margins and deliver on its business plan.

The upcoming March 19 investor event is another focal point, with some research highlighting it as a potential catalyst if management provides more clarity on medium term revenue growth and the trajectory of earnings.

Bullish analysts also highlight themes such as affordable medicines and capital allocation priorities, including references to buybacks and debt reduction in recent upgrades, as supporting pillars for their more constructive stance on valuation.

Bullish Takeaways

Multiple bullish analysts have raised Viatris price targets into the mid teens up to $20, signaling greater confidence in the company’s plan and supporting the higher fair value estimate cited earlier.
UBS points to completed Q4 cost saving targets and FY26 guidance above prior consensus as key supports for its $20 target, tying the higher valuation to visible execution on efficiency and profit improvement.
Recent upgrades referencing expected buybacks and debt reduction suggest some analysts see Viatris’ capital allocation as a positive driver that could support earnings per share and, in turn, justify a stronger P/E multiple.
Research pointing to affordable medicines as an attractive theme, alongside the upcoming March 19 investor event, frames a set of potential growth and information catalysts that bullish analysts see as important for re rating potential.

What's in the News

Updated 2026 guidance: Viatris expects total revenue in fiscal 2026 in a range of US$14.45b to US$14.95b, with a midpoint of US$14.70b (Corporate guidance).
Share repurchase progress: Between October 1, 2025 and December 31, 2025, Viatris repurchased 8,054,726 shares for US$82.16 million, completing a total of 94,176,848 shares repurchased for US$1,000.06 million under the buyback program announced on February 28, 2022 (Buyback tranche update).
Eye care pipeline update: The FDA accepted for review a supplemental New Drug Application for MR-141 (phentolamine ophthalmic solution 0.75%) seeking to expand its indication to include presbyopia, with a PDUFA goal date of October 17, 2026, and related VEGA-3 data expected to be presented at major ophthalmology conferences in April and May (Product-related announcement).
Cardiovascular portfolio expansion: Viatris launched Inpefa (sotagliflozin) in the United Arab Emirates, its first territory launch for this heart failure treatment, with regulatory filings submitted in several additional countries including Canada, Australia and Mexico (Product-related announcement).

Valuation Changes

Fair Value: Raised from $16.00 to $20.00, a 25% increase in the fair value estimate.
Discount Rate: Effectively unchanged at 6.978% in both the prior and updated assessment.
Revenue Growth: Assumption lifted from 2.03% to 3.45%, indicating a higher projected top line growth rate.
Net Profit Margin: Assumption increased from 3.19% to 13.30%, reflecting a much higher expected level of profitability.
Future P/E: Assumption reduced from 42.33x to 12.64x, implying a lower valuation multiple applied to future earnings.

5 views

Key Takeaways

Rapid advancement of innovative products and biosimilars, coupled with unrivaled emerging-market presence, is set to boost growth and diversify earnings streams.
Deep integration, cost-saving initiatives, and strategic asset moves could unlock greater structural efficiencies, supporting sustained high profitability and cash flow.
Pressure from global drug pricing reforms, operational and regulatory risks, and high leverage threaten Viatris' growth prospects, profitability, and long-term earnings stability.

Catalysts

About Viatris

Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.What are the underlying business or industry changes driving this perspective?

While analyst consensus anticipates new revenue and margin gains from innovative products like selatogrel, cenerimod, and meloxicam, the scale and speed of positive Phase III readouts across multiple blockbuster candidates could significantly outpace expectations, accelerating a large step-change in both top-line growth and high-margin contributions by 2026.
Analysts broadly agree that upcoming cost-saving initiatives will improve future margins, but the ongoing enterprise-wide strategic review-combined with further asset divestitures and deep integration post-merger-could unlock far greater operational efficiencies than modeled, resulting in structural margin expansion and sustained high free cash flow.
Viatris is now emerging as a dominant platform in the global biosimilar market, well-positioned to rapidly capture share as governments and health systems worldwide accelerate adoption of biosimilars for cost containment, significantly lifting revenues and pushing long-term margin trajectories higher.
The company's unparalleled commercial scale in emerging markets, combined with expanding access to healthcare and robust brand presence in regions like Greater China and emerging Asia, is set to drive sustained double-digit revenue growth and further diversify earnings streams.
Viatris' resilient global manufacturing footprint-including strategic U.S.-based production and a shift toward complex generics-uniquely positions the company to capitalize on industry disruptions from regulatory or trade policy changes, minimizing risk and maximizing profitability in the face of potential headwinds affecting less-diversified peers.

Viatris Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more optimistic perspective on Viatris compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
The bullish analysts are assuming Viatris's revenue will grow by 3.4% annually over the next 3 years.
The bullish analysts assume that profit margins will increase from -24.6% today to 13.3% in 3 years time.
The bullish analysts expect earnings to reach $2.1 billion (and earnings per share of $1.9) by about March 2029, up from -$3.5 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $651.9 million.
In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 12.6x on those 2029 earnings, up from -4.3x today. This future PE is lower than the current PE for the US Pharmaceuticals industry at 16.6x.
The bullish analysts expect the number of shares outstanding to decline by 1.9% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Persistent global regulatory efforts to reform drug pricing, especially targeting generic products, could sustain downward pressure on Viatris' core generics business, leading to constrained revenue growth and reduced net margins over time.
Viatris' heavy reliance on new pipeline launches for mid
and long-term growth carries execution and timing risks, as delays or setbacks in product approvals or launches could undercut future revenue streams and stall earnings growth.
Ongoing remediation requirements and unresolved FDA classifications at key manufacturing sites, such as Indore and Nashik, highlight operational risk and regulatory scrutiny, which may result in increased costs, supply constraints, and weaker profitability in coming years.
The company's high leverage resulting from the Mylan-Upjohn merger limits its financial flexibility, increases interest expenses, and restricts strategic investment in R&D or business development, threatening future net margins and long-term earnings sustainability.
Increasing competition from biosimilars, global moves towards healthcare digitization, and consolidation among pharmacy benefit managers and large customers amplify pricing and market share pressures, posing long-term headwinds to Viatris' revenue and earnings stability.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bullish price target for Viatris is $20.0, which represents up to two standard deviations above the consensus price target of $15.5. This valuation is based on what can be assumed as the expectations of Viatris's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $20.0, and the most bearish reporting a price target of just $12.0.
In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $15.8 billion, earnings will come to $2.1 billion, and it would be trading on a PE ratio of 12.6x, assuming you use a discount rate of 7.0%.
Given the current share price of $13.2, the analyst price target of $20.0 is 34.0% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Viatris?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Emerging Markets And Global Aging Will Elevate Biosimilars